Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing products for therapeutic areas with significant unmet medical need. Its core technology is the proprietary Diffusphere platform, which optimizes drug delivery to improve efficacy and safety. The company’s lead product candidate is EP-104IAR, currently in Phase III clinical trials for the treatment of knee osteoarthritis. Additionally, EP-104GI is in Phase II trials for eosinophilic esophagitis, and EP-104 is under preclinical studies for gastrointestinal conditions such as eosinophilic esophagitis. Eupraxia aims to address chronic inflammatory and pain conditions through targeted, sustained-release therapies.

Eupraxia Pharmaceuticals Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol EPRX. Its securities trade in U.S. dollars (USD). The company is headquartered in Victoria, Canada, but its shares are available to investors on the U.S. exchange, providing access to a broad base of international investors.

Eupraxia Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly those leveraging its Diffusphere drug delivery technology. The company targets inflammatory and pain-related conditions, such as knee osteoarthritis and eosinophilic esophagitis, which are areas with high unmet medical need.

Eupraxia Pharmaceuticals Inc. is headquartered in Victoria, Canada. The company was incorporated in 2011 and was formerly known as Plaza Capital Partners Inc. before rebranding to its current name in May 2012. Since then, it has focused on advancing its pipeline of product candidates, all based on its Diffusphere technology platform, to address chronic inflammatory diseases.

Eupraxia Pharmaceuticals' pipeline is centered on its Diffusphere drug delivery technology. The lead candidate, EP-104IAR, is in Phase III clinical trials for knee osteoarthritis, aiming to provide sustained pain relief. EP-104GI is in Phase II trials for eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. Additionally, EP-104 is in preclinical development for gastrointestinal disorders, including eosinophilic esophagitis. These candidates are designed to improve patient outcomes by optimizing drug release and targeting specific tissues.